arrow
S

Shinsuke Iida

Nagoya City University Hospital
H指数:61
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world treatment patterns and clinical outcomes in relapsed/refractory multiple myeloma across Asia: a multicenter Asian Myeloma Network study (AMN010)

亚洲多发性骨髓瘤网络研究(AMN010):亚洲复发/难治性多发性骨髓瘤的真实世界治疗模式与临床结局

2026-11-110
OAAI
Targeting Overexpressed IDO in Stromal Cells as a Potential Therapeutic Strategy in Multiple Myeloma

靶向基质细胞中过表达的IDO作为多发性骨髓瘤的潜在治疗策略

2025-11-010
OAAI
Germline or somatic mutations in genes encoding microRNAs as biomarkers predicting the risk of adult T-cell leukemia/lymphoma

生殖细胞系或体细胞中编码microRNA的基因的突变作为预测成人T细胞白血病/淋巴瘤风险的生物标志物

2025-10-200
PRE
Prognostic Impact of Clinical Factors and Cell Composition of Apheresis Samples on BCMA CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma

临床因素及单采样本细胞组成对复发或难治性多发性骨髓瘤BCMA CAR-T细胞治疗的预后影响

BLOOD
IF23.1
2024-11-050
PRE
A novel T cell-redirecting anti-GPRC5D x CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models

在多发性骨髓瘤临床前模型中具有有效抗肿瘤活性的新型T细胞重定向anti-GPRC5D x CD3双特异性抗体

2024-03-013
OAAI
Clinical landscape of TP73 structural variants in ATL patients
LEUKEMIA
IF13.4
2023-10-201
OAAI
A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan

日本复发/难治性多发性骨髓瘤患者伊扎佐米联合来那度胺-地塞米松的前瞻性、多中心、观察性研究

2023-09-112
OAAI